DSI
NBIX icon

Daiwa SB Investments’s Neurocrine Biosciences NBIX Stock Holding History

Daiwa SB Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,954
Closed -$90K – 249
2017
Q2 		$90K Buy
+1,954
New +$94.8K 0.02% 164

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Daiwa SB Investments's NBIX Position: Q3 2017 in Review

Daiwa SB Investments sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 1,954 shares — an estimated $90K sold.

Daiwa SB Investments first reported a position in NBIX in Q2 2017 and held it in 1 quarter. The position peaked at $90K in Q2 2017. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

  • Daiwa SB Investments reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
  • Daiwa SB Investments sold 1,954 Neurocrine Biosciences shares in Q3 2017, an estimated $90K.
  • Daiwa SB Investments first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 1 quarter.
  • Daiwa SB Investments's Neurocrine Biosciences position peaked at $90K in Q2 2017.
  • 223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Daiwa SB Investments's 13F filing for Q3 2017, filed 13 Oct 2017.